287 related articles for article (PubMed ID: 23720197)
1. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
[TBL] [Abstract][Full Text] [Related]
2. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
[TBL] [Abstract][Full Text] [Related]
3. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
7. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
[TBL] [Abstract][Full Text] [Related]
9. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
Urba S; van Herpen CM; Sahoo TP; Shin DM; Licitra L; Mezei K; Reuter C; Hitt R; Russo F; Chang SC; Hossain AM; Frimodt-Moller B; Koustenis A; Hong RL
Cancer; 2012 Oct; 118(19):4694-705. PubMed ID: 22434360
[TBL] [Abstract][Full Text] [Related]
12. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Tsai YS; Tzai TS; Chow NH
Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
[TBL] [Abstract][Full Text] [Related]
13. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma.
Louvet C; de Gramont A; Tournigand C; Artru P; Maindrault-Goebel F; Krulik M
Cancer; 2001 Jun; 91(11):2033-8. PubMed ID: 11391582
[TBL] [Abstract][Full Text] [Related]
14. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR; Bellmunt J; Fougeray R; Choueiri TK; Qu AQ; Niegisch G; Albers P; Di Lorenzo G; Salhi Y; Galsky MD; Agarwal N; Necchi A; Sonpavde G
Clin Genitourin Cancer; 2013 Dec; 11(4):495-500. PubMed ID: 23800847
[TBL] [Abstract][Full Text] [Related]
15. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
[TBL] [Abstract][Full Text] [Related]
17. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group.
Galsky MD; Hendricks R; Svatek R; Bangs R; Hoffman-Censits J; Clement J; Dreicer R; Guancial E; Hahn N; Lerner SP; O'Donnell PH; Quale DZ; Siefker-Radtke A; Shipley W; Sonpavde G; Vaena D; Vinson J; Rosenberg J
Cancer; 2013 Jun; 119(11):1994-8. PubMed ID: 23456777
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
[TBL] [Abstract][Full Text] [Related]
19. Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study.
Rose PG; Ali S; Whitney CW; Lanciano R; Stehman FB
Gynecol Oncol; 2011 Jun; 121(3):542-5. PubMed ID: 21420157
[TBL] [Abstract][Full Text] [Related]
20. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
